VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Scher on Using the Circulating Tumor Cells Test

Howard I. Scher, MD
Published: Thursday, Jun 30, 2011

Howard I. Scher, MD, chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering, lead author of the COU-AA-301 trial that investigated circulating tumor cells (CTC), describes using the CTC test; a blood test designed to assess the prognosis of patients with metastatic cancer.

Dr. Scher says one of the reasons they were able to use the test in the trial was because samples could be processed up to 72 hours after the blood is drawn. They got all samples from North America sent to Memorial Sloan-Kettering, but there are also several reference laboratories that can perform the test. Some hospitals that don't see a lot of patients may not want to invest in the technology on their own, but it can be sent to reference laboratories and be performed, and have the results be available.
Howard I. Scher, MD, chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering, lead author of the COU-AA-301 trial that investigated circulating tumor cells (CTC), describes using the CTC test; a blood test designed to assess the prognosis of patients with metastatic cancer.

Dr. Scher says one of the reasons they were able to use the test in the trial was because samples could be processed up to 72 hours after the blood is drawn. They got all samples from North America sent to Memorial Sloan-Kettering, but there are also several reference laboratories that can perform the test. Some hospitals that don't see a lot of patients may not want to invest in the technology on their own, but it can be sent to reference laboratories and be performed, and have the results be available.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x